Abstract
Context: Prostate cancer screening is highly controversial, including the age to begin prostate-specific antigen (PSA) testing. Several studies have evaluated the usefulness of baseline PSA measurements at a young age. Objective: Review the literature on baseline PSA testing at a young age (<= 60 yr) for the prediction of prostate cancer risk and prognosis. Evidence acquisition: PubMed was searched for English-language publications on baseline PSA and prostate cancer for the period ending April 2011. Evidence synthesis: In most published series, median PSA levels in the general male population range from approximately 0.4 to 0.7 ng/ml in men in their 40s and from approximately 0.7 to 1.0 ng/ml in men in their 50s. Evidence from both nonscreening and screening populations has demonstrated the predictive value of a single baseline PSA measurement for prostate cancer risk assessment. Specifically, men with baseline PSA levels above the age-group-specific median have a greater risk of prostate cancer diagnosis during the next 20-25 yr. Additional studies confirmed that higher baseline PSA levels at a young age are also associated with a greater risk of aggressive disease, metastasis, and disease-specific mortality many years later. Conclusions: Baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Thus baseline PSA testing may be used for risk stratification and to guide screening protocols. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 1-7 |
| Number of pages | 7 |
| Journal | European Urology |
| Volume | 61 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research programs
- EMC MM-03-49-01
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver